Pegylated interferon-alpha 2a treatment of chronic SIV-infected macaques.
J Med Primatol
; 37(1): 26-30, 2008 Feb.
Article
en En
| MEDLINE
| ID: mdl-18199069
ABSTRACT
BACKGROUND:
In vitro and clinical observations in HIV-infected patients receiving interferon alpha therapy have shown a reduction in HIV loads. Limited investigations have explored the innate or adaptive immune responses of IFN-alpha on SIV replication in vivo.METHODS:
Seven chronically infected rhesus macaques were given pegylated IFN-alpha 2a (n = four) or saline (n = three) injections once weekly for 14 weeks. Weekly peripheral blood samples were taken for safety parameters, viral load determinations, and measurements of innate and adaptive immune responses.RESULTS:
Pharmacokinetic measurements demonstrated therapeutic peg-IFN-alpha levels for the initial period of therapy and IFN-alpha inducible antiviral molecules were increased sporadically in the PBMC mRNA of the treatment group. Despite the demonstrable effect of the IFN-alpha injections, the treatment had no effect on plasma viral RNA levels.CONCLUSIONS:
This work demonstrates that while short term IFN-alpha therapy induces innate antiviral immunity, it does not dramatically enhance or suppress viral replication. However, studies in the SIV model to determine therapeutic potential of chronic IFN-alpha therapy for the treatment of HIV will require macaque specific cytokines.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Antivirales
/
Polietilenglicoles
/
Síndrome de Inmunodeficiencia Adquirida del Simio
/
Interferón-alfa
/
Macaca
/
Enfermedades de los Monos
Límite:
Animals
Idioma:
En
Revista:
J Med Primatol
Año:
2008
Tipo del documento:
Article
País de afiliación:
Estados Unidos